×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Antibody-Drug Conjugate Drug Development: From Novel Technology to New Patient Therapy
Session Chair(s)
Angela Qu, MD, PhD
Vice President, Translational Medicine
Parexel, United States
In this session, the expert speakers will describe and discuss the key learnings from this cutting-edge and arguably intriguing topic and promote open thoughts on how to innovate next-generation of ADC development and identify new opportunities to broaden ADC applications to deliver new therapies to help fulfill unmet medical needs.
Learning Objective : Illustrate up-to-date ADCs drug development landscape along with therapeutic applications and opportunities; Describe scientific rationales for Antibody-Drug Conjugate (ADC) drug design and novel technological platforms; Discuss case studies of novel ADCs development from bench to clinical and from clinical to successful launch; Discuss strategic and operational considerations unique to ADC including key challenges and translational needs for ADC drugs from preclinical into clinical.
Speaker(s)
The Evolution of Antibody-Drug Conjugates in the Era of Precision Medicine Development
Angela Qu, MD, PhD
Parexel, United States
Vice President, Translational Medicine
Bispecific ADC Technology Platforms and M1231: A Bispecific ADC Targeting EGFR and MUC1
Joern-Peter Halle, PhD
Merck KGaA, Germany
Senior Vice President, Global Head of Research
Before the DREAMM: Preclinical Findings Leading to Development of Belantamab Mafodotin
Joanna B. Opalinska, MD
GlaxoSmithKline, United States
Senior Director, Oncology Clinical Development
Have an account?